Working… Menu

Olaparib Dose Escalating Trial + Concurrent RT With or Without Cisplatin in Locally Advanced NSCLC (olaparib)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01562210
Recruitment Status : Completed
First Posted : March 23, 2012
Last Update Posted : March 17, 2020
Information provided by (Responsible Party):
The Netherlands Cancer Institute